MetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR Pathway.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28923857.
- Also identified by DOI 10.1158/0008-5472.CAN-17-0671.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Long noncoding RNAs (lncRNA) participate in carcinogenesis and tumor progression in lung cancer. Here, we report the identification of a lncRNA signature associated with metastasis of non-small cell lung cancer (NSCLC). In particular, elevated expression of LINC00963 (MetaLnc9) in human NSCLC specimens correlated with poor prognosis, promoted migration and invasion of NSCLC cells <i>in vitro</i>, and enhanced lung metastasis formation <i>in vivo</i> Mechanistic investigations showed that MetaLnc9 interacted with the glycolytic kinase PGK1 and prevented its ubiquitination in NSCLC cells, leading to activation of the oncogenic AKT/mTOR signaling pathway. MetaLnc9 also interacted with P54nrb/NonO (NONO) to help mediate the activity of CRTC, a coactivator for the transcription factor CREB, reinforcing a positive feedback loop for metastasis. Taken together, our results establish MetaLnc9 as a driver of metastasis and a candidate therapeutic target for treating advanced NSCLC. <i>Cancer Res; 77(21); 5782-94. ©2017 AACR</i>.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Phosphoglycerate Kinase
- Proto-Oncogene Proteins c-akt
- RNA, Long Noncoding
- TOR Serine-Threonine Kinases